Screener
Halozyme Therapeutics HALO Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's free cash flow?
- Halozyme Therapeutics (HALO) reported free cash flow of $236.72M in Q2 2026.
- How has Halozyme Therapeutics's free cash flow changed year-over-year?
- Halozyme Therapeutics's free cash flow increased by 141.2% year-over-year, from $98.15M to $236.72M.
- What is the long-term trend for Halozyme Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's free cash flow has grown at a 21.3% compound annual growth rate (CAGR), from $297.98M to $644.59M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Halozyme Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude